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Abstract
Background: The aim was to investigate new markers for type 2 diabetes (T2DM) dyslipidemia related with LDL
and HDL metabolism. Removal from plasma of free and esterified cholesterol transported in LDL and the transfer of
lipids to HDL are important aspects of the lipoprotein intravascular metabolism. The plasma kinetics (fractional
clearance rate, FCR) and transfers of lipids to HDL were explored in T2DM patients and controls, using as tool a
nanoemulsion that mimics LDL lipid structure (LDE).
Results: 14C- cholesteryl ester FCR of the nanoemulsion was greater in T2DM than in controls (0.07 ± 0.02 vs.
0.05 ± 0.01 h-1, p = 0.02) indicating that LDE was removed faster, but FCR 3 H- cholesterol was equal in both groups.
Esterification rates of LDE free-cholesterol were equal. Cholesteryl ester and triglyceride transfer from LDE to HDL
was greater in T2DM (4.2 ± 0.8 vs. 3.5 ± 0.7%, p = 0.03 and 6.8 ± 1.6% vs. 5.0 ± 1.1, p = 0.03, respectively). Phospholipid
and free cholesterol transfers were not different.
Conclusions: The kinetics of free and esterified cholesterol tended to be independent in T2DM patients and the
lipid transfers to HDL were also disturbed. These novel findings may be related with pathophysiological
mechanisms of diabetic macrovascular disease.
Keywords: Type 2 diabetes mellitus, Lipoprotein, Low density lipoprotein, High density lipoprotein, Lipid transfer,
Nanoparticles, Emulsion
Background
Dyslipidemia of type 2 diabetes mellitus (T2DM) is con-
sequent to alterations in key processes of the plasma
lipid metabolism modulated by insulin, such as lipolysis
by lipoprotein lipase and hormone-sensitive lipase [1-3].
The function of cell receptors that remove lipoproteins
from the plasma is also influenced by insulin [4-6].
T2DM dyslipidemias characterized by accumulation of
triglyceride-rich lipoproteins, such as VLDL, as well as
low HDL cholesterol. Diabetic dyslipidemia predisposes
to development of cardiovascular disease [7-10], the
major cause of mortality of those patients [9,11,12].
LDL cholesterol concentration is not typically increased
in T2DM but LDL is subjected to important changes in
this disease, such as increase in the small, dense LDL sub-
class, that is considered the most atherogenic [13-15]. Like
the other lipoprotein classes, LDL contains both forms of
cholesterol, the free and the esterified form [2,3]. Free
cholesterol is located in the surface layer of the lipoprotein
particles and can easily diffuse in the surrounding aqueous
medium. Cholesteryl esters are located in the lipoprotein
core wherein they are more stable than the free form
[2,16,17]. In the circulation, free cholesterol is esterified by
the action of lecithin cholesterol acyl transferase (LCAT),
using apolipoprotein (apo) A1 as a co-factor [2,3]. This
process occurs mainly in HDL, because most of the apo
A1 pool is found in this fraction [16,17]. HDL receives free
cholesterol, phospholipids and other lipids from the other
lipoprotein classes and from cells of peripheral tissues.
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Transfer of free cholesterol from cells to HDL is mediated
by ATP-binding cassette transport 1 (ABCA1) system.
The process of lipid transfers among lipoprotein
classes is mediated by transfer proteins, such as choles-
teryl ester transfer protein (CETP) and phospholipid
transfer protein (PLTP) [2,3]. Lipid transfers are essential
parts of cholesterol reverse transport and are particularly
important in HDL metabolism. This lipoprotein is
formed into the intravascular compartment by lipidation
of apo A1, originating disks that, with further acquisition
of lipids and cholesterol esterification, changes into
round-shaped particles [2,3], so that HDL is constantly
being remodeled. As presence of T2DM may change the
activity of the transfer proteins [18,19], the lipid trans-
fers to HDL and the HDL metabolism may also be
affected [20].
In previous studies [21-27], we explored the intravas-
cular metabolism of free and esterified cholesterol car-
ried in an artificial nanoemulsion (LDE) that mimics the
lipidic structure of LDL but does not contain protein. In
this approach, LDE is doubly labeled with 14C-cholesteryl
esters and 3H-cholesterol and injected intravenously in a
bolus; blood is sequentially sampled for determination of
the plasma kinetics of both labels. In contact with plasma,
LDE acquires exchangeable apolipoproteins such as apo E
[21,22] that endows the nanoemulsion to bind to LDL
receptors [23,25]. The validity of the LDE method to test
the LDL metabolism in the clinical setting was shown in
several studies [21-27].
LDL metabolism can be altered even in presence of
normal LDL cholesterol levels. Increase in small dense
LDL subfraction is exemplary for this situation, and it
has been shown the benefits of cholesterol lowering by
statin treatment administered to normocholesterolemic
T2DM patients [28,29]. In this setting, the current study
aimed to investigate whether the kinetics in the plasma
of free and esterified cholesterol and the lipid transfers
to HDL are altered in T2DM patients with normal LDL
cholesterol. LDE labeled with 14 C-cholesteryl esters and
3H-cholesterol was used to probe this metabolism in
cases versus control subjects. LDE was also used as lipid
donor to HDL in an in vitro assay [30] to test in both
groups the simultaneous transfer of free and esterified
cholesterol, phospholipids and triglycerides to HDL.
Results
As shown in Table 1, the glycemic control of the partici-
pant T2DM patients was not good, as judged by their
HbA1c levels. The concentration of total serum choles-
terol and total serum free cholesterol, as well as the LDL
cholesterol concentration, were similar in T2DM and
controls. HDL cholesterol tended to be lower in T2DM
patients, although this difference did not attain statistical
significance (p = 0.06). Serum triglyceride concentration
was higher in T2DM (p = 0.05). Apo A1, apo B and apo
E did not differ between the two groups.
The plasma decay curves of both nanoemulsion labels
are shown in Figure 1. While the free cholesterol curves
of T2DM patients and controls were similar, the choles-
teryl ester curve seems faster in the patients than in
controls.
Indeed, the removal from the plasma of the nanoemul-
sion cholesteryl esters was faster in T2DM than in con-
trols (Figure 1), as confirmed by their greater FCR of
this label (p = 0.02, Table 2). As expected from inspection
of the curves in Figure 1, the two groups showed similar
FCR of the free cholesterol (p = 0.75).
Table 3 shows the percentual of transfer from the
donor nanoemulsion lipids to the HDL fraction after 1 h
incubation of the nanoemulsion with whole plasma.
Patients with T2DM showed increased transfer of the
core lipids, namely cholesteryl esters (p = 0.03) and tri-
glycerides (p = 0.03), to HDL than the controls. In con-
trast, the transfer of the surface lipids, phospholipids
and free cholesterol, were similar.
Discussion
T2DM patients who were on metformin treatment alone
or with additional sulphonylurea or insulin, showed in
average poor glycemic control together with mild to
high-triglycerides and borderline low HDL cholesterol.
This conforms to a typical T2DM dyslipidemia.
In the T2DM patients, LDL cholesterol was normal
and did not differ from the values from the control sub-
jects. In those patients, the removal from the plasma of
the cholesteryl ester component of LDE was faster than
that measured in the control subjects. As the cholesteryl
ester FCR closely depicts the removal from the plasma
Table 1 Serum biochemical parameters of the the Type 2
Diabetes Mellitus (T2DM) and Control groups
T2DM Control P
(n = 15) (n = 11)
Fasting plasma glucose (mmol/L) 9.4 ± 5.3 4.6 ± 0.4 <0.01
HbA1c (%) 8.9 ± 1.9 5.6 ± 0.4 <0.01
Cholesterol (mmol/L) 4.7 ± 1.0 4.9 ± 0.9 0.61
Non-HDL 3.6 ± 0.9 3.4 ± 0.8 0.59
LDL 2.9 ± 0.4 2.8 ± 0.7 0. 60
HDL 1.1 ± 0.3 1.5 ± 0.6 0.06
Triglycerides (mmol/L) 2.1 ± 1.3 1.3 ± 0.6 0.05
Free Cholesterol (mmol/L) 1.5 ± 0.3 1.5 ± 0.4 0.96
Apolipoproteins (g/L)
A1 1.34 ± 0.21 1.53 ± 0.40 0.19
B 0.95 ± 0.25 0.87 ± 0.20 0.38
E 0.05 ± 0.02 0.04 ± 0.01 0.29
Data are means ± SD.
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of the LDE particles, it can be assumed that inT2DM
patients LDE was cleared more efficiently than control
subjects. A plausible interpretation for this result resides
Figure 1 Plasma decay curve of 14 C-cholesteryl ester (A) and 3H-cholesterol (B) obtained from type 2 diabetes mellitus (black square)
and control (white square) groups. The doubly labeled nanoemulsion was intravenously injected in a bolus, and blood samples were drawn in
pre-established intervals over 24 h for measurement of the radioactivity in a scintillation solution. Data are expressed as mean± SD.
Table 2 Fractional Clearance Rates and kinetic
parameters of LDE radioactive lipid labels in the Type 2
Diabetes Mellitus (T2DM) and Control groups
T2DM Control P
(n = 15) (n = 11)
FCR 14 C-CE (h-1) 0.07 ± 0.02 0.05 ± 0.01 0.02
k 1.0
14 C-CE 0.30 ± 0.15 0.30 ± 0.26 0.91
k 1.2
14 C-CE 0.90 ± 1.20 0.97 ± 1.44 0.44
k 2.0
14 C-CE 0.05 ± 0.02 0.03 ± 0.01 0.02
FCR 3 H-C(h-1) 0.05 ± 0.02 0.05 ± 0.02 0.75
k 1.0
3 H-C 0.88 ± 0.83 0.86 ± 0.63 0.88
k 1.2
3 H-C 0.89 ± 1.02 0.90 ± 1.02 1.00
k 2.0
3 H-C 0.02 ± 0.01 0.03 ± 0.02 1.00
Data are express as mean ± SD. LDE, non-protein LDL-like nanoemulsion. 14 C-
CE, 14 C-cholesteryl ester. 3 H-C, 3 H-cholesterol.
Table 3 Lipid transfer in vitro from LDE to HDL particles
of the Type 2 Diabetes Mellitus (T2DM) and Control
groups
T2DM Control P
(n = 15) (n = 11)
3 H- cholesteryl ester (%) 4.2 ± 0.8 3.5 ± 0.7 0.03
14 C-phosphatidylcholine (%) 24.1 ± 2.7 22.0 ± 0.9 0.15
3 H- triglycerides (%) 6.8 ± 1.6 5.0 ± 1.1 0.03
14 C- cholesterol (%) 9.2 ± 3.0 7.5 ± 2.6 0.23
Data are expressed as mean ± SD. The value indicated is the percentage of the
radioactivity of each lipid component in the nanoemulsion that was
transferred to the plasma HDL fraction after 1 h incubation.
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on that all the study patients were on use of metformin.
The mechanism of action of this drug is related at least
partially with activation of AMP- activated protein kin-
ase (AMPK) [31]. It has been shown that AMPK
decreases hydroxyl-methilglutaryl- CoA reductase activ-
ity, leading to upregulation of LDL receptors [32,33]. Be-
cause, similarly to native LDL [34], LDE is removed by
LDL receptors [21,24,25], it is conceivable that metfor-
min use elicited the accelerated LDE cholesteryl ester
clearance observed in T2DM.
In contrast, it is noteworthy that the free cholesteryl
component of LDE was removed at similar rates in
T2DM and in controls. This could suggest that the free
form of cholesterol is released from the LDE particles
while in the circulation [24,26], possibly being trans-
ferred to the native lipoprotein classes [30] that are
removed slower than LDE [22]. Another possibility
stands on the selective uptake of cholesteryl esters by
cells of liver and macrophages [35,36], that could accel-
erate the removal from the plasma of those components
without changing the free cholesterol removal in T2DM
patients. In lipoprotein structure, free cholesterol, which
is located in the particle surface, is more unstable than
cholesteryl esters which is placed in the particle core.
The esterified form depends on the transfer proteins to
exit the lipoprotein but free cholesterol may diffuse into
the surrounding aqueous media and thereafter may be
incorporated into other lipoproteins or cell membranes.
Tracing of the lipid components of native LDL in the
circulation of subjects is not practical, due to the diffi-
culties of the labeling technique, which makes the
nanoemulsion approach particularly useful. Thus, to our
knowledge, this is the first study in which the kinetics of
free and esterified cholesterol were explored in diabetes.
In studies in which the clearance of native LDL labeled
in the apo B component was determined, LDL clearance
has been described as greater, equal or smaller [37-40]
than in controls. Those contradictory results can be
ascribed to many intervening factors, such as different
treatments or plasma lipid profiles of the patients.
The important aspect of HDL metabolism investigated
here, the process of lipid transfers to the lipoprotein, is de-
terminant of HDL composition and metabolism. Thus, it
is likely that atheroprotective functions of the lipoprotein
may also be affected by lipid transfers, such as the antioxi-
dant, anti-inflammatory, antithrombotic, and vasodilator
actions [20]. In previous studies, we showed that HDL
transfers were altered in precocious coronary artery dis-
ease [41] and in patients with heart grafts [42], a condition
that is associated with development of heart graft coron-
ary disease, an accelerated atherosclerosis process. In the
current study, T2DM patients showed increased transfers
of triglycerides and cholesteryl esters that make-up the
lipoprotein core, whereas the transfer of phospholipids
and free cholesterol that are the constituents of lipopro-
tein surface was not affected [41,42]. This finding is prob-
ably related with the increase in action of CETP that may
occur in T2DM [16,17] and facilitating the transfer of core
lipids. Enrichment of HDL with triglycerides is related
with loss of function and stability of the lipoprotein
[1,16,17]. This has been ascribed to the interactions of
HDL with hepatic lipase that lead to acceleration of the
lipoprotein clearance and reduction of HDL plasma levels
[17]. In fact, it was observed here a trend for lower HDL–
cholesterol in the T1DM group. In a previous study, we
compared lipid transfers to HDL measured in T2DM
without microalbuminuria with those with microalbumi-
nuria, that is a more advanced disease stage and no differ-
ence was found between the two groups. This may
suggest that aggravation of diabetes complications does
not interfere with the lipid transfers [43].
As a limitation of this study, non-protein LDE has dif-
ferences in chemical composition regarding LDL, and
also differs in binding to LDL receptors by recognition
of apo E rather than apo B [22], as in the native lipopro-
tein [34]. Nonetheless, as shown in several studies
[21,24,26,27], by using LDE as probe for the LDL meta-
bolic pathway in case–control protocols it is possible to
detect alterations in diseased states and under the effect
of drugs [24] that could be fairly extrapolated to native
LDL metabolism. As the groups of T1DM and controls
had similar apo E plasma concentrations, it can be
assumed that apo E adsorption to LDE particles did not
influence FCR of the nanoemulsion.
Conclusion
The independent removal from the plasma of the free
and of the esterified forms of cholesterol despite normal
LDL cholesterol levels and the alterations in the lipid
transfers to HDL found in T2DM suggest the existence
of novel pathophysiologic pathways that can eventually
be related with diabetic macrovascular disease.
Methods
Study subjects
The participants in the study were selected from the Out-
patient Clinics of the Endocrinology Section of the Hos-
pital of the University of São Paulo Medical School. The
inclusion criteria were men and postmenopausal women,
with 40 to 70 years of age without previous history of car-
diovascular disease. Ten out of fifteen of the T2DM
patients and five out of eleven of the control subjects pre-
sented systemic arterial hypertension and were on antihy-
pertensive drugs and well controlled with a maximum
systolic blood pressure of 130 mmHg and diastolic of
85 mmHg. Regarding the lipid levels total cholesterol
was≤ 6 mmol/L and LDL≤ 4 mmol/L. The exclusion cri-
teria were the use of medications that have significant
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action on lipid metabolism such as statins, fibrates, gluco-
corticoids and thiazolidinediones, presence of nephropa-
thy (the presence of microalbuminuria, as indicated to
urinary ratio microalbuminuria/creatinine <30 μg/mg and
serum creatinine below 98 μmol/L in women and 115 μmol/
L in men), proliferative retinopathy and neuropathy. Furthe-
more, the presence of chronic diseases such as heart failure,
chronic obstructive pulmonary disease, inflammatory disease
and cancer were also exclusion factors. T2DM patients had
the duration of the disease less than 15 years. The character-
istics of the study patients are depicted in Table 4. T2DM
diabetes mellitus patients had mean known duration of dis-
ease 8±4.0 years. There were no differences between both
groups regarding age and sex distributions, but the
patients had higher BMI (p< 0.01) and waist circumference
(p< 0.05) than controls. All were being treated with metfor-
min, but 8 were also treated with sulfonylurea (glyburide),
2 also with insulin and 2 with additional insulin and
sulphonylurea.
Serum biochemical analysis
Blood samples for determination of laboratorial para-
meters were collected after 12 h fast on the same day the
kinetic study were preformed. Commercial enzymatic
colorimetric methods were used for the determination of
total cholesterol, triglycerides and HDL cholesterol. LDL
cholesterol was calculated by a direct method (Roche
Diagnostics, Mannheim, Germany). Plasma apo A1 and
apo B were assayed by turbidimetry (Roche Diagnostics)
and apo E by nephelometry (Roche Diagnostics), Glyco
Hemoglobin (HbA1c) was measured by HPLC (National
Glyco Hemoglobin Standardization Program - NGSP-
USA, considering normal range 4,1 a 6%).
LDE preparation
LDE was prepared from a lipid mixture composed of
40 mg cholesteryl oleate, 20 mg egg phosphaditylcholine,
1 mg triolein and 0.5 mg of cholesterol purchased from
Sigma Chemical (St. Louis, MO). 14C- cholesteryl oleate
and 3H- cholesterol purchased from PerkinElmer (Wal-
tham, MA) were added to the mixture. Emulsification of
lipids by prolonged ultrasonic irradiation in aqueous
media and the procedure of two-step ultracentrifugation
of the crude emulsion with density adjustment by addition
of KBr to obtain LDE was carried out as described by
Maranhão et al. [22]. The final lipidcomposition of LDE
was 64% phospholipids, 33% cholesteryl oleate, 2% triacyl-
glycerols, and 1% cholesterol [20]. LDE was dialyzed
against a saline solution and sterilized by passage through
0.22-μm filter for injection into the patients. The entire
LDE preparation procedure was performed in a laminar
flux. All glassware used in this study was made pyrogen
free by exposure to dried steam at 180°C for 2hand steri-
lized by wet steam at 120°C for 30 min. All plastic materi-
als were sterilized by exposure to ultraviolet light.
Nanoemulsion plasma kinetics
All the patients were asked to arrive at the laboratory by
7 a.m. after a 12 h fasting. The basal collection of blood
samples was done for the blood assays, as explained pre-
viously. LDE labeled with14C-cholesteryl oleate (37 kBq)
and 3H-cholesterol (74 kBq), in a total 5–6 mg in a vol-
ume 500 μL was intravenously injected in a bolus. Blood
samples were taken over 24 h (5’, 1 h, 2 h, 4 h, 6 h, 8 h
and 24 h). Participants were allowed to eat low-fat
meals, on the evening before the test day and after the
first blood collection and at about 1:00 p.m., since it is
known that low-fat meals do not interfere with plasma
removal of the LDE [21]. Plasma samples were separated
by centrifugation and 1 mL was transferred to counting
vials containing 5 mL scintillation solution, and counted
in a scintillation counter (1600 TR model, Hewlett-Pack-
ard, Palo Alto, CA).
Estimation of fractional clearance rate of the
radioisotopes
Fractional clearance rate (FCR) of 14 C-cholesteryl ester
and 3H-free cholesterol contained in LDE was calculated
Table 4 Physical characteristics and current medications
of the Type 2 Diabetes Mellitus (T2DM) and Control
groups
T2DM Control P
N 15 11
Age (years) 58.9 ± 4.8 54.6 ± 5.5 0.06
Sex (M/F) 7/8 5/6 1.00
Weight (kg) 82.1 ± 11.7 74.9 ± 7.3 0.08
BMI (kg/m2) 31.9 ± 4.6 27.1 ± 2.4 <0.01
Waist Circumference (cm) 104.9 ± 9.8 94.2 ± 7.3 <0.01
Arterial Hypertension 10 5 0.43
Familial history CVD 5 5 0.69
Current smoking 3 2 0.22
Current medications
Metformin 15 - -
Sulfonylurea 8 - -
Insulin 4 - -
ACEi 9 4 0.39
ARB 1 1 1.00
Ca channel blockers 3 2 0.49
Thiazides 2 1 1.00
AAS 4 0 0.10
Data are means ± SD. CVD, cardiovascular disease. ACEi, angiotensin-
converting enzyme inhibitor. ARB, angiotensin II receptor blocker. Ca, calcium.
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according to the method described elsewhere [27] e Silva
et al. 2011 [44], defined by the sum of two exponential
functions, obtained from the remaining radioactivity
found in plasma after injection, as y = (a1.e
-b
1
t + a2.e
-b
2
t ),
where y is the curve the radioactivity plasma decay in
function of time (t); a indicates the linear coefficient and
b the angular coefficient, which represents the FCR in
hours-1 (h-1). The model consists of two discrete pools,
one intravascular pool in dynamic equilibrium with an
extravascular pool, assuming that all input or exit of the
radiolabeled lipid occurs from the intravascular pool.
The fractional clearance rate of the radiolabeled lipid
was estimated as FCR= (a1/b1 + a2/b2)
-1, which is essen-
tially the inverse of the area under the activity-time
curve. Calculations were performed using the ANA-
COMP computer software [45]. The compartmental
model is illustrated in Figure 2.
Lipid transfer from LDE to HDL in vitro
The transfer rates of cholesteryl ester, phospholipid, free
cholesterol, and triglyceride from LDE to HDL were
measured according to Lo Prete et al. [30]. Plasma with
EDTA in a volume of 200 μL was incubated with 50 μL
of the nanoemulsion labeled either with 3H-cholesteryl
oleate and 14 C-phosphatidylcholine, or with 3H-triolein
and 14 C-cholesterol. After a 1-h incubation on a shaker
in a water bath at 37°C, 250 μL dextran sulfate/MgCl2
0,2%/MgCl2 3 M, v/v were added as a precipitating re-
agent. The solution was then mixed for 30 s and centri-
fuged for 10 min at 3000 g. Finally, 250 μL of the
supernatant was added to counting vials containing
5 mL scintillation solution (Packard BioScience, Gro-
ningen, Netherlands). Radioactivity was measured with a
liquid scintillation analyzer, as described above. The
blank samples consisted of 200 μL Tris solution with
added labeled nanoemulsion and the precipitation re-
agent after incubation, as described above. The results of
the radioactive transfer from the lipid nanoemulsions to
the HDL fractions were expressed as a percentage of the
total incubated radioactivity, determined in a plasma
sample containing no precipitation reagents. The above
described assay was validated for precision according to
Food and Drug Administration Guidelines [46] in which
the upper limit is 5%. Intra-assay precision studies
included 10 replicates of samples. Inter-assay precision
was calculated based on 3 assays of 10 replicates, run on
3 different days. Intra-assay coefficient of variation was
0.83% for phospholipids, 0.56% for free cholesterol,
1.49% for esterified cholesterol and 0.51% for triglycer-
ides indicating consistent reproducibility. Inter-assay
showed no difference between samples for transfer of all
lipids (phospholipids = 0.78; free cholesterol = 0.59; es-
terified cholesterol = 1.32; triglycerides = 0.58). The assay
was performed with maximum plasma storage of two-
months after sample collection. As previously tested, the
storage of the plasma samples at -80°C up to 1-year had
no effect on the lipid transfer results [30].
Informed consent and radiological safety
The experimental protocol was approved by the Ethics
Committee of the Medical School Hospital of the Uni-
versity of São Paulo and all participants provided written
informed consent. The safety of the radioactive dose
intravenously injected into the patients was assured
according to the regulations of the International Com-
mission on Radiological Protection [47]. The injected
dose on each experiment was 0.03mSV.
Statistical analysis
Data normality was tested by the Kolmogorov-Smirnov
procedure. Data are expressed as mean± standard error
of the mean. Non- parametric test were performed:
Mann–Whitney test, for normally distributed variables
and by Fischer Exact test (2- tail), for categorical vari-
able. In all analysis difference of two tail p< 0,05 was
considered statically significant. It was used SPSS version
15.0 (IBM Company, Chicago, Illinois, USA) for Win-
dows XP (Microsoft Corporation, Redmond, Washigton,
USA) for all the analysis.
Figure 2 Compartmental model used for analysing LDE 14 C-
cholesteryl ester (14 C-CE) and 3H-cholesterol curves (3 H-FC).
The model consists of four discrete compartments: two for 14 C-CE
and two for 3 H-FC labels. All compartments are in the intravascular
space (1CE, 2CE, 1FC and 2 FC). LDE, a non-protein lipoprotein
nanoemulsion labeled with 14 C-CE and 3 H-FC were injected
intravenously in a bolus (arrow with asterisk) into compartment 1CE
and 1FC, respectively. A fraction k1,0CE and k1,0 FC of the labeled lipids
is removed to the extravascular space. Competitively, fraction k1,2CE
and k1,2FC of the injected lipids are converted into compartments
2CE and 2FC due to the incorporation of apolipoproteins available in
the plasma. Subsequently, the material of those compartments are
transferred to the extravascular space following the k2,0CE and k2,0FC
routes. The samplings, represented by triangles correspond to the
indiscriminate combination of compartments 1 and 2.
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